GeneDx Holdings Corp (NASDAQ: WGS) closed the day trading at $9.13 down -3.49% from the previous closing price of $9.46. In other words, the price has decreased by -$0.33 from its previous closing price. On the day, 116443 shares were traded.
Ratios:
For a better understanding of WGS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.95 and its Current Ratio is at 3.10. In the meantime, Its Debt-to-Equity ratio is 0.53 whereas as Long-Term Debt/Eq ratio is at 0.51.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 18 ’24 when Stueland Katherine sold 8,559 shares for $10.59 per share. The transaction valued at 90,661 led to the insider holds 66,698 shares of the business.
Feeley Kevin sold 3,253 shares of WGS for $34,455 on Mar 18 ’24. The CHIEF FINANCIAL OFFICER now owns 28,927 shares after completing the transaction at $10.59 per share. On Mar 18 ’24, another insider, Saad Kareem, who serves as the CHIEF TRANSFORMATION OFFICER of the company, sold 2,008 shares for $10.59 each. As a result, the insider received 21,269 and left with 29,517 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WGS now has a Market Capitalization of 246.47M and an Enterprise Value of 236.09M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.17 while its Price-to-Book (P/B) ratio in mrq is 1.04. Its current Enterprise Value per Revenue stands at 1.17 whereas that against EBITDA is -1.73.
Stock Price History:
The Beta on a monthly basis for WGS is 2.83, which has changed by -9.85% over the last 52 weeks, in comparison to a change of 29.57% over the same period for the S&P500. Over the past 52 weeks, WGS has reached a high of $12.24, while it has fallen to a 52-week low of $1.16. The 50-Day Moving Average of the stock is 6.45, while the 200-Day Moving Average is calculated to be 4.69.
Shares Statistics:
Over the past 3-months, WGS traded about 270.01K shares per day on average, while over the past 10 days, WGS traded about 242.4k shares per day. A total of 25.98M shares are outstanding, with a floating share count of 16.22M. Insiders hold about 37.76% of the company’s shares, while institutions hold 42.36% stake in the company. Shares short for WGS as of Mar 15, 2024 were 1.05M with a Short Ratio of 3.90, compared to 1.21M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.04% and a Short% of Float of 20.24%.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of -$0.54 and a low estimate of -$0.77, while EPS last year was -$2.44. The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.53 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.82 and -$2.36 for the fiscal current year, implying an average EPS of -$2.07. EPS for the following year is -$0.89, with 3 analysts recommending between -$0.31 and -$1.37.
Revenue Estimates
4 analysts predict $49.52M in revenue for the current quarter. It ranges from a high estimate of $50.5M to a low estimate of $47.3M. As of the current estimate, GeneDx Holdings Corp’s year-ago sales were $43.14M, an estimated increase of 14.80% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $55.24M, an increase of 13.40% less than the figure of $14.80% in the same quarter last year. There is a high estimate of $56.99M for the next quarter, whereas the lowest estimate is $53.6M.
A total of 4 analysts have provided revenue estimates for WGS’s current fiscal year. The highest revenue estimate was $228.14M, while the lowest revenue estimate was $224M, resulting in an average revenue estimate of $226.1M. In the same quarter a year ago, actual revenue was $202.57M, up 11.60% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $265.45M in the next fiscal year. The high estimate is $275.1M and the low estimate is $255M. The average revenue growth estimate for next year is up 17.40% from the average revenue estimate for this year.
